Michael T Yin1, Ellen S Chan2, Todd T Brown3, Jennifer Kinslow4, Jeffrey Martinson4, Alan Landay4, Kathleen M Melbourne5, Heather J Ribaudo2, Edgar T Overton6. 1. Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. 2. Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA, USA. 3. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Microbial Pathogens and Immunity, Rush Medical College, Chicago IL, USA. 5. Gilead Sciences, Foster City, CA, USA. 6. Department of Medicine, University of Alabama, Birmingham, AL, USA.
Abstract
BACKGROUND:Vitamin D (VitD) and calcium (Ca) supplementation attenuates antiretroviral therapy (ART)-associated bone loss, but it is unclear whether this effect is mediated through immunomodulation. METHODS: In this exploratory analysis of A5280, a 48-week, randomized, double-blind, placebo-controlled study of VitD/Ca supplementation with ART initiation, we characterized lymphocyte phenotypes and receptor activator of nuclear factor kappa-B ligand (RANKL) expression by median fluorescence intensity (MFI) at baseline and 48 weeks. Changes were evaluated within and between treatment groups by Wilcoxon signed rank and rank sum tests, respectively. Spearman correlations estimated relationships between cellular phenotypes and bone mineral density (BMD). RESULTS: Of 165 participants enrolled, 138 had samples for cellular phenotypes (64 VitD/Ca, 74 placebo). Markers of CD4, CD8 activation (CD38+HLA-DR+) declined (all P<0.001), but did not differ between arms. There was no decline in either %T-cells (CD4 and CD8) expressing RANKL or expression of RANKL by MFI. CD4 and CD8 activation markers were not correlated with BMD at baseline (r<0.15 and P>0.09 for all), but greater declines in CD4 activation correlated with greater declines in hip and spine BMD in both arms (0.25 ≤r ≤0.37, all P<0.05). A greater decline in CD8 activation was correlated with greater declines in both hip and spine BMD in the placebo arm only (hip r=0.31, P=0.009; spine r=0.25, P=0.035). CONCLUSIONS: Reductions in T-cell activation are characteristic of ART initiation, but only correlated modestly with bone loss. VitD/Ca supplementation does not appear to mitigate bone loss through modulation of immune activation or expression of RANKL. TRIAL REGISTRATION NUMBER: NCT01403051.
RCT Entities:
BACKGROUND:Vitamin D (VitD) and calcium (Ca) supplementation attenuates antiretroviral therapy (ART)-associated bone loss, but it is unclear whether this effect is mediated through immunomodulation. METHODS: In this exploratory analysis of A5280, a 48-week, randomized, double-blind, placebo-controlled study of VitD/Ca supplementation with ART initiation, we characterized lymphocyte phenotypes and receptor activator of nuclear factor kappa-B ligand (RANKL) expression by median fluorescence intensity (MFI) at baseline and 48 weeks. Changes were evaluated within and between treatment groups by Wilcoxon signed rank and rank sum tests, respectively. Spearman correlations estimated relationships between cellular phenotypes and bone mineral density (BMD). RESULTS: Of 165 participants enrolled, 138 had samples for cellular phenotypes (64 VitD/Ca, 74 placebo). Markers of CD4, CD8 activation (CD38+HLA-DR+) declined (all P<0.001), but did not differ between arms. There was no decline in either %T-cells (CD4 and CD8) expressing RANKL or expression of RANKL by MFI. CD4 and CD8 activation markers were not correlated with BMD at baseline (r<0.15 and P>0.09 for all), but greater declines in CD4 activation correlated with greater declines in hip and spine BMD in both arms (0.25 ≤r ≤0.37, all P<0.05). A greater decline in CD8 activation was correlated with greater declines in both hip and spine BMD in the placebo arm only (hip r=0.31, P=0.009; spine r=0.25, P=0.035). CONCLUSIONS: Reductions in T-cell activation are characteristic of ART initiation, but only correlated modestly with bone loss. VitD/Ca supplementation does not appear to mitigate bone loss through modulation of immune activation or expression of RANKL. TRIAL REGISTRATION NUMBER: NCT01403051.
Authors: Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Michael T Yin; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen M Melbourne; Andrew Napoli; William R Hardin; Heather J Ribaudo; Edgar T Overton Journal: AIDS Date: 2017-11-13 Impact factor: 4.177
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Edgar Turner Overton; Ellen S Chan; Todd T Brown; Pablo Tebas; Grace A McComsey; Kathleen M Melbourne; Andrew Napoli; William Royce Hardin; Heather J Ribaudo; Michael T Yin Journal: Ann Intern Med Date: 2015-06-16 Impact factor: 25.391
Authors: Allison Ross Eckard; Mary Ann O'Riordan; Julia C Rosebush; Seungeun Thera Lee; Jakob G Habib; Joshua H Ruff; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Ann Chahroudi; Grace A McComsey Journal: Antivir Ther Date: 2018
Authors: Ighovwerha Ofotokun; Lauren F Collins; Kehmia Titanji; Antonina Foster; Caitlin A Moran; Anandi N Sheth; Cecile D Lahiri; Jeffrey L Lennox; Laura Ward; Kirk A Easley; M Neale Weitzmann Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079